（来源：南京晨报） 转自：南京晨报 糖尿病足疮面久治不愈，下肢常年肿胀形成"橡皮腿"，房颤患者突然出现肢体怕冷、麻木疼痛、皮肤颜 色改变、溃疡……出现这些症状还不当回事或者病急乱投医？江苏省中西医结合医院普外科副主任中医 师景海波提醒，这些都是周围血管病的表现，血管不健康，从头伤到脚，轻则致残、重则危及生命。 景海波介绍，周围血管病是发生在心脏和大脑以外血管的疾病，主要是为四肢、内脏供血的动脉、静脉 和淋巴管出现了问题。常见疾病包括动脉硬化导致下肢动脉闭塞、血栓脱落导致急性动脉栓塞、血管扩 张膨出形成动脉瘤或夹层，深静脉血栓、下肢静脉曲张等。该病发病隐匿，偏爱有长期吸烟习惯，患有 高血压、高血糖、高血脂、房颤，以及需要久站久坐等人群。早期不易发觉，患者常从出现手脚发凉麻 木，逐渐发展成走路腿痛、皮肤变色，腿沉、肿胀，伤口长期不愈合或持续溃烂。 出现这些问题怎么办？江苏省中西医结合医院目前设有血管外科（脉管科）专病门诊，中西结合一站式 精准诊疗周围血管病。该科由江苏省名中西医结合专家顾亚夫教授带头创建，顾老在长期临床研究中， 创立"养阴祛瘀"学术经验，针对周围血管病发病特点及多种临床表现，充分发挥中医药治疗优势 ...

Core Insights - Jinling Pharmaceutical (000919) reported a total revenue of 3.281 billion yuan for 2024, representing a year-on-year increase of 2.74%, while the net profit attributable to shareholders was only 40.41 million yuan, a decline of 61.95% [1][2] Financial Performance - The company's core products, such as the injection of Maizuo Ning and Su Li Fei (ferrous succinate), did not effectively support revenue growth, with pharmaceutical production and sales achieving 1.493 billion yuan, down 3.93% year-on-year [2] - Jinling Pharmaceutical's net profit has been declining for three consecutive years, with figures of 121 million yuan, 105 million yuan, and 99.65 million yuan from 2021 to 2023 [3] Assets and Liabilities - As of December 31, 2024, Jinling Pharmaceutical's total assets were 6.089 billion yuan, an increase of 10.86% year-on-year, with cash holdings of 1.771 billion yuan, accounts receivable of 439 million yuan, and inventory of 272 million yuan [2] - The total liabilities stood at 1.24 billion yuan, up 14.79% year-on-year, including accounts payable of 557 million yuan and prepayments of 1.26 million yuan [2] R&D and Strategic Initiatives - In response to performance pressures, Jinling Pharmaceutical increased its R&D expenditure to 111 million yuan, a rise of 39.86%, indicating a focus on innovation to enhance product competitiveness [4] - The number of R&D personnel grew from 131 in 2023 to 153 in 2024, representing a 16.79% increase, with R&D staff now making up 3.16% of the total workforce [4] - The company is also expanding its healthcare and wellness sector, having completed the acquisition of a 51% stake in Nanjing Meishan Hospital to enhance its market presence [4] Future Growth Plans - Jinling Pharmaceutical plans to raise 750 million yuan, with 600 million yuan allocated to the Hefei Jinling Tianyi Smart Elderly Care Project, which aims to provide intelligent elderly care and rehabilitation services [5] - The company is exploring new revenue growth points amid declining profits and has not yet responded to inquiries regarding its strategy to reverse the trend of falling net profits [5]